NDAORALTABLETPriority Review
Approved
Jul 2018
Lifecycle
Peak
Competitive Pressure
0/100
Clinical Trials
20
Data completeness
5/8 — Partial
Priority Review
ORILISSA (elagolix) by AbbVie is gland. First approved in 2018.
Drug data last refreshed 9h ago · AI intelligence enriched 1w ago
AI summarySynthesized from FDA + DailyMed + ClinicalTrials.gov data
ORILISSA (elagolix) is an oral gonadotropin-releasing hormone (GnRH) antagonist approved in 2018 for the management of moderate to severe endometriosis pain. It works by suppressing luteinizing hormone (LH) and follicle-stimulating hormone (FSH), leading to decreased estradiol and progesterone concentrations. The drug represents a non-surgical, hormonal treatment option for women with endometriosis seeking pain relief.
$0.004BPart D
Peak14.2 years to LOEProduct is in peak lifecycle stage with modest Part D uptake (~2,600 claims in 2023), suggesting stable but limited market penetration and a focused commercial team.
Mechanism of Action
gland. Administration of ORILISSA results in dose-dependent suppression of luteinizing hormone (LH) and follicle-stimulating hormone (FSH), leading to decreased blood concentrations of the ovarian sex hormones, estradiol and progesterone.
Indications
Indication data is being enriched from DailyMed and FDA labeling. Check back soon for approved therapeutic uses.
Clinical Trials (20)
A Study to Evaluate Safety and Efficacy of Elagolix in Patients With Moderate to Severe Endometriosis-Associated Pain
Started Sep 2022
336 enrolled
Endometriosis
A Study to Evaluate Pregnancy Outcomes in Females Treated With Oral Elagolix Tablets and Capsules
Started Jan 2022
173 enrolled
EndometriosisUterine Fibrioids
Study to Gather Information How Well Three Different Doses of BAY1817080 Given Twice Daily Over 12 Weeks Work in Comparison to an Inactive Pill (Placebo) and Elagolix in Women Suffering From Pain Related to a Condition Where the Tissue That Usually Grows Inside the Womb Grows Outside of the Womb
Started Jan 2021
215 enrolled
Endometriosis
Study Of Oral Elagolix Tablets To Assess the Tolerability and Change in Disease Symptoms in Adult Female Participants With Moderate to Severe Endometriosis-associated Pain
Started Dec 2020
117 enrolled
Endometriosis
Comparison Elagolix vs Depot Leuprolide Prior to Frozen Embryo Transfers in Patients With Endometriosis
Started Sep 2020
30 enrolled
InfertilityEndometriosis
Worked on ORILISSA at AbbVie? Share your interview experience or compensation data (+7 days Pro)
Data Sources
- Drug label: DailyMed / FDA
- Clinical trials: ClinicalTrials.gov
- Patent data: FDA Orange Book
- Spending data: CMS Medicare
The information on this page is for informational purposes only and should not be used as a substitute for professional medical advice. Drug information is sourced from FDA, DailyMed, and other government databases. Adverse event data from FAERS does not establish causation. Always consult a healthcare professional for medical decisions.